Business Context and Reporting Period
This Form 8-K was filed by Hemispherx Biopharma, Inc. on June 1, 2017, reporting events occurring on the same date. The filing details a material definitive agreement regarding the exercise of previously issued warrants by institutional investors. Note: The request metadata references "AIM Immunotech Inc.," but the filing text explicitly identifies the registrant as Hemispherx Biopharma, Inc.
Key Financial Metrics and Transaction Details
- Transaction Type: Exercise of Offered Warrants and issuance of new warrants.
- Shares Purchased: 2,370,000 shares of Common Stock (with an anticipated additional 130,000 shares).
- Exercise Price Adjustment: Reduced from $2.00 to $0.50 per share.
- Gross Proceeds: Approximately $1,185,000 (plus up to $65,000 if remaining warrants are exercised).
- New Warrants Issued:
- Series A Warrants: 2,370,000 shares at $0.60/share (expires March 6, 2022).
- Series B Warrants: 7,584,000 shares at $0.60/share (3-month exercise window starting 6 months post-issuance).
- Placement Agent Fees: 7% cash fee on proceeds, 1% management fee, $25,000 expense reimbursement, plus warrants for 107,759 shares at $0.625/share.
Material Changes Versus Prior Period
The filing does not provide comparative financial statements or revenue/profit metrics for a prior period. The material change reported is the restructuring of the warrant exercise terms, specifically the reduction of the exercise price to $0.50 and the issuance of significant new warrant tranches (Series A and B) to facilitate the transaction.
Guidance, Outlook, and Risks
- Use of Proceeds: Funds will be used for operating and administrative expenses, manufacturing, research and development, and working capital.
- Regulatory Status: The issuance of new warrants and shares is exempt from registration under Section 4(a)(2) of the Securities Act and Rule 506(b).
- Contingencies: New Warrants include cashless exercise provisions if an effective registration statement is not available when they become exercisable.
- Outlook: The filing does not contain specific forward-looking guidance on revenue or clinical milestones beyond the stated use of funds.
Key Facts for Investor Verification
- Verify the total dilution impact of the 9,954,000 new warrants (Series A and B combined) relative to the current share count.
- Confirm the actual cash proceeds received, as the $1,185,000 figure is contingent on the exercise of the remaining 130,000 Offered Warrants.
- Review the attached Exhibits 10.1, 4.1, and 4.2 for full terms regarding anti-dilution adjustments and cashless exercise mechanics.
- Assess the company's cash runway given the stated use of proceeds for R&D and manufacturing without immediate revenue generation.